Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV(TM) (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer

Breakthrough Therapy Designation Based on Initial Results from Phase 1b/2 EV-103 Clinical Trial TOKYO and BOTHELL, Wash., Feb. 19, 2020 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.... Biopharmaceuticals, Oncology, FDA Astellas Pharma, Seattle Genetics, Enfortumab Vedotin, Urothelial Cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news